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IMAGING PERFORMANCE OF A GD2O2S:PR,CE,F SCINTILLATOR COATED
CMOS IMAGING SENSOR
C. Michail a, I. Seferis a,b, I. Valais a, V. Koukou c, N. Kalyvas a, A. Bakas d, G.
Fountos a, I. Kandarakis a. aDepartment of Biomedical Engineering,
Technological Educational Institute of Athens,122 10 Athens, Greece;
b Faculty of Chemistry, Wroclaw University, 14F Joliot-Curie Street, 50-383
Wroclaw, Poland; cDepartment of Medical Physics, School of Medicine,
University of Patras, Rion GR 26504, Greece; dMedical Radiological
Technology, Faculty of Health and Caring Professions / Technological
Educational Institution of Athens, Athens, Greece
Aim: The aim of the present study was to investigate the imaging per-
formance of gadolinium oxysulﬁde powder scintillators, doped with pra-
seodymium, cerium and ﬂuorine (Gd2O2S:Pr,Ce,F) coupled to a high
resolution active pixel CMOS imaging sensor.
Methods: Gd2O2S:Pr,Ce,F is a non-hygroscopic material, emitting green
light with short decay time. For the purposes of this study, a scintillating
screen with coating thickness of 35.7 mg/cm2, was prepared in
our laboratory from powder (Phosphor Technology, Ltd) by sedimentation
on silica substrates. The CMOS sensor was coupled to the Gd2O2S:Pr,Ce,F
scintillator screen. Imaging performance was obtained by means of
experimentally determined parameters such as the signal transfer prop-
erties (STP), the modulation transfer function (MTF) and the normalized
noise power spectrum (NNPS). Measurements were performed using the
standard IEC-RQA5 radiation beam quality (70 kVp).
Results: It was found that the detector response function was linear for
the exposure range under investigation. At 70 kVp, under the RQA 5
conditions, the Gd2O2S:Pr,Ce,F/CMOS combination can resolve 6.88 cy-
cles/mm, at MTF10% and the noise levels were found to decrease from
6.42X10-6 mm2, at 1.38 cycles/mm to less than 2.23X10-6 mm2 at 5.2 cy-
cles/mm.
Conclusion: MTF and NNPS values of the Gd2O2S:Pr,Ce,F/CMOS combi-
nation were found with high values suggesting an acceptable imaging
performance showing potential interest for non-CT medical imaging (i.e.
dental radiology) or industrial digital radiography.
Acknowledgement: This research has been co-funded by the European
Union (European Social Fund) and Greek national resources under the
framework of the “ARISTEIA” project MISCIRLU code 1476 of the “Educa-
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APPLICATION OF TUMOR BED BOOST BY TWO DIFFERENT METHODS
Zygogianni Anna M.D,Ph.D a, Kouloulias Vassilios M.Sc., M.D,
Ph.D b, Kyrgias George M.D,Ph.D c, Armpilia Christina M.Sc a, Antypas
Christos M.Sc., Ph.D a, Theodorou Kiki M.Sc., Ph.D c, Kouvaris John
M.D,Ph.D a. aKapodistrian University of Athens, Medical School, 1st
Radiology Department, Aretaieion Hospital, Greece; bKapodistrian
University of Athens, Medical School, 2st Radiology Department, Attikon
Hospital, Greece; cUniversity of Thessalia, Medical School, Radiotherapy
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Aim: We evaluate acute and late radiation toxicity, and the
effectiveness of the radiation therapy of the two radiotherapeutic
hypofractionated schedules using two different planning techniques of
delivering radiation boost using 3D conformal radiation therapy
(3DCRT).
Method: Eight one patients were studied, between May 2004 and
December 2010. The patients were retrospectively selected regarding with
either concomitant (group A) or sequential (group B) boost for tumor bed
in two groups. In the ﬁrst group, 27 patients received 2.3 Gy up to 46 Gy in
the whole breast tissue and it was added a concomitant boost covering
tumor bed as a second daily fraction of 0.4 Gy, so that the total tumor bed
boost was 54 Gy. In the second group, 54 patients received radiotherapy
with a total prescription dose of 53Gy by 2.65Gy per fraction, in 20
fractions, over 25 days. The last four fractions were delivered as a
sequential tumor boost. Using the linear quadratic model, BED has been
calculated for the whole breast dose and total boost dose volumes. These
values in the ﬁrst radiotherapy regimen used were 72.5 Gy4 and 90.5 Gy4 ,
respectively. In the second one they were 70.5 Gy4 and 88.1 Gy4,
respectively.
Results: The statistical analysis of the comparison between the two
methods, showed that cosmetic results, in terms of skin toxicity score, was
signiﬁcantly worse in integrated boost group, for time ranging from the
completion of radiotherapy until 12th months thereafter. After the ﬁrst
year post irradiation the toxicity was reduced to minimum in both groups,
while the Kruskal-Wallis H Test showed a signiﬁcant (P<0.05) superiority
of group B in skin toxicity in terms of overall follow-up. With a median
follow up of 24 months, no patient showed local or regional disease
recurrence.
Conclusions: There were signiﬁcant differences in the scoring of ery-
thema, in patients receiving an incorporated boost compared with patients
treated by sequential boost. The higher skin reactions were observed in the
group with the concomitant boost and especially identiﬁed in the appli-
cation area of the intergraded boost. This can be avoided by the application
of IMRT technique whereas the dose distribution is more smooth and
homogeneous
SOFT-TISSUE MATCHING METHODS FOR LUNG CANCER RADIOTHERAPY
- BENEFITS, LIMITATIONS AND MARGIN DETERMINATION
Fatma Rahma a,b, Wiviann Ottosson a,c, Claus F. Behrens a, David
Sj€ostr€om a, Patrik Sibolt a. aDepartment of Oncology, Radiotherapy Research
Unit, HerlevHospital, University of Copenhagen, DK-2730 Herlev, Denmark;
bDepartment of Medical Radiation Physics, Clinical Sciences, Lund
University, Sweden; cCenter for Nuclear Technologies, TechnicalUniversity
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Background: The purpose of this study was to evaluate ﬁve different CBCT
semi-automatic soft-tissue match methods for lung cancer patients and to
calculate the corresponding CTV to PTV margins, both for primary tumor
and lymphnodes.
Material and methods: For 23 lung cancer patients (16 NSCLC, 7 SCLC)
treated with radiotherapy, 135 weekly CBCT set-up images were retro-
spectively matched to the planning CTs byﬁve different match methods
using the registration software Ofﬂine Review, version 10.0 (Varian
Medical Systems). Four match methods utilized the volume of interest
(VOI) of the 4DCT deﬁned GTV, including the internal motion (GTV-T/
IM), plus a 2, 5, 10 or 20 mmsymmetrical margin, respectively. The ﬁfth
match method used a square VOI enclosing the GTV-T with a 10 mm
symmetrical margin. An intensity range of [-150;150] HU was used for
automatic soft-tissue matches. Residual GTV-T/IM set-up deviations in
all directions were studied for each match and PTV-T margins were
calculated. Additionally, stable surrogates close to GTV-N was used for
the residual GTV-N set-up deviation measurements and PTV-N margin
calculations.
Results: All match methods gave similarresidual GTV-T/IM set-up de-
viations, ranging between [0;3] mm (62 % within 0-1 mm, 34 % within 1-2
mm, and 4% within 2-3 mm), resulting in [5.2;5.8] mm PTV-T margins.
Match methods utilizing larger VOIs were more stable compared to match
methods using smaller VOIs. Auto match on small targets (<3 cm3) was
problematic, and not possible for match method 5. For 77 % of the patients
with lymph nodes, the main bronchi area was a suitable stable surrogate.
For the remaining lateral GVT-Ns the aortic arch and the main pulmonary
artery were suitable as surrogates. Residual GTV-N set-up deviations
ranged between [-8;10] mm resulting in PTV-N margins between [6;9.8]
mm.
Discussion: Forsemi-automatic soft-tissuematch on the primary tumor,-
match within GTV-T/IM witha 10 or 20 mmmargin extensionused as
matching VOIs were most appropriate. For small tumors (<3 cm3),
matching manually on GTV-T/IM itself is advisable. The main bronchi
area is a suitable surrogate primarily for centrally positionedmediastinal
GTV-N.
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MODELLING BIOGRAPH 2 PET/CT SCANNER WITH GATE
D. Nikolopoulos a, I. Valais b, C. Michail b, S. Kottou c, N. Chatzisavvas a, P.
Yannakopoulos a, V. Malaxianakis b. aDepartment of Computer Electronic
Engineering, Technological Education Institute of Piraeus, Greece, Petrou
Ralli & Thivon 250, 122 44, Aigaleo, Athens, Greece; bDepartment of
Biomedical Engineering, Technological Educational Institute of of Athens,
Agiou Spiridonos, 12210, Aigaleo, Greece; cMedical Physics Department,
Medical School, University of Athens, Greece
Background: A commercial PET scanner (Siemens, Biograph 2) previously
tested through experiments according to the NEMA NU-2-2001 protocol,
was simulated, using the GATE v.6.1 open source software.
Materials and methods: The study aimed: (a) to port previously
developed and validated GATE codes to the more stable version of
GATE v.6.1; (b) to evaluate the overall applicability and validity of the
model and to investigate potential sources of bias (c) to examine
possible alterations in the results caused by different employed sources,
i.e. F-18 (Fluorine-18), O-15 (Oxygen-15) and C-11 (Carbon-11). All
modules of the Biograph 2 scanner were described in GATE, namely
the detector ring, crystal blocks, PMTs, shielding, electronics etc. In
addition, the energy and spatial resolution of the employed detectors
and their contribution to the overall system’s efﬁciency were taken into
account.
Results: The results derived by the simulations with GATE, were then
compared to the experimental data obtained by the NEMA NU-2-2001
protocol. Scatter fraction, count loses and randomswere themain points of
interest.
Discussion: Good agreement was observed between the results of the
experimental data and GATE simulated results.
ASSESSMENT OF DOSE ADMINISTRATION CONSISTENCY IN PET/CT
N. Sgouros a, T. Stroubinis a, A. Samartzis a, P. Rondogianni a, I.
Datseris a. aDepartment of Nuclear Medicine, Evangelismos General
Hospital, Athens , Greece
Background: In this work we assess the consistency of the dose admin-
istration process of 18F-FDG in the PET/CT establishment of Evangelismos
General Hospital. In detail, we retrospectively assess the dose adminis-
tration accuracy for a three year period and evaluate the dose consistency
over two shifts. Both shifts utilized an ANZAI medical semi-automated
dispenser. In the ﬁrst shift trainees are supervised by experienced medical
physicists while in the second shift dose administrationwas performed by
experienced professionals.
Materials and methods: The data utilized in this study were collected
from 2011 through the end of 2013 and were properly anonymized by
removing patients’ demographic details. The resulting sample after
removing invalid entries contains 4038 records.
In order to robustly assess the administration accuracy the initially pre-
pared (PD ) and syringe residual doses (RD ) were measured and the
nominal dose (ND ) for each patient was calculated. In order to provide a
robust and simple measure we utilized ratio r calculated by Eq. 1 and
already proposed by the authors.
r ¼ PD RD
ND
(1)
Results: In order to examine the accuracy of dose administration the
Shapiro e Wilk test is us ed for testing normality of the r values distri-
butions prior to using the t-test. The mean values, standard deviations and
the p-values for the Shapiro - Wilk test and the t-test are summarized in
Table 1.
As shown in Table 1 both group samples follow the normal distribution
(p>0.05) and have mean values very close to unity which is in line with
the design of quantity r . Furthermore, comparison of the standard de-
viations qualiﬁes both samples for the t-test. The t-test shows (p>0.05)
that the two populations have normal distributions with equal mean
values.
Discussion: The results show that there is no signiﬁcant difference in dose
administration distributions between trainees and professionals. This fact
is attributed in part to the semi-automated dispenser used in the process
and in part to the standardization of the process and supervision of the
medical physicists during the shift where trainees administer the doses.
Hence consistent and homogeneous dose administration is achieved
throughout both shifts assuring proper dose delivery to the patients of the
PET/CT setup.
Figure 1. GTV-T/IM residual deviation after 3DOF soft-tissue match (utilizing GTV-T/
IM plus a 2, 5, 10 and 20 mm symmetrical margin, and square VOI enclosing the
GTV-T with a 10 mm symmetrical margin).
Table 1. Calculated Statistics
Groups Mean value Standard
Deviation
p-values
Shapiro - Wilk t-test
Trainees 0.9849 0.054 0.2538 0.8539
Professionals 0.9882 0.043 0.3102
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